PolyNovo Limited (PNV) Fair Value & Analysis
Healthcare · AU · Market cap A$715M
Fair value as of: Aug 13, 2026
From 15 valuation models · updated yesterday
Fair value updated Aug 13, 2026, revised from A$0.3300 to A$0.3200 (−3.0%) since Jul 12, 2026. Share price −5.9% over the past month.
A solid business, but screening 67% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (A$0.4000). The favourable scenario is already priced in.
- Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range A$0.8450 – A$2.88 · fair‑value band A$0.2400 – A$0.4000 · the A$0.9650 price screens above the A$0.3200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
PolyNovo Limited (PNV) currently trades at A$0.9650, while our model-based Fair Value estimate is A$0.3200, implying the stock looks roughly 66.8% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, PolyNovo Limited generated revenue of A$139M at a net margin of 7.1%. Revenue grew 18.1% year over year. It earns a return on equity of 12.5%. The balance sheet holds a net cash position of A$16.4M. Fundamentals as of Aug 13, 2026
Our scenario range runs from A$0.2400 (bear case) to A$0.4000 (bull case); at A$0.9650, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -67%, PNV screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: Growth Earnings (A$0.8900) versus Asset-Based (A$0.0800). Highest evidence: Residual Income (76).
Notify me when PNV reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 25
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn.
Full company description
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PolyNovo Limited reported revenue of A$127M in FY2025 versus A$29.2M in FY2021, a compound +44.5%/yr. Reported net income was A$13.2M in FY2025.
PNV screens 67% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 346 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
Compare PolyNovo Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PolyNovo Limited (PNV) overvalued or undervalued?
What is the fair value of PNV?
What is the quality score of PNV?
What is the revenue of PolyNovo Limited (PNV)?
What is the net profit margin of PNV?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PolyNovo Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.